ReviewFrontiers in oncology2025
Navigating tumour microenvironment in endometrial carcinoma: a comprehensive review integrating immunohistochemistry, single-cell RNA-sequencing and spatial transcriptomics.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating artificial intelligence and multi-omics data for precision oncology in endometrial cancer: a narrative review.Functional & integrative genomics · 2026Review
- Redefining the Treatment Landscape of Advanced Endometrial Cancer in the Era of Immunotherapy and Precision Oncology.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is regarded as one of the most prevalent malignancies in women globally. Despite the advancements brought by multiple therapeutic strategies, the efficacy and effectiveness of treatment still appear to be diminished. Therefore, this accentuates the importance of understanding the tumour microenvironment (TME). Conventional methods, including immunohistochemistry (IHC), along with recently emerged techniques like single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST), have rejuvenated the notion of deciphering TME. From deconstructing tumour heterogeneity, identifying cell populations that play significant roles in treatment response, to discovering key biomarkers and therapeutic targets, these technologies lay the base for innovations. Importantly, this is the first comprehensive review that brings together scRNA-seq, ST, and IHC in Endometrial cancer. Merging these methods is geared towards creating a better grasp of the dynamics and interactions between diverse cells and the TME.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.